Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

BACKGROUND: First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occurring almost exclusively in intrahepati...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou-Alfa, Ghassan K., Bibeau, Kristen, Schultz, Nikolaus, Yaqubie, Amin, Millang, Brittanie, Ren, Haobo, Féliz, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512879/
https://www.ncbi.nlm.nih.gov/pubmed/36114955
http://dx.doi.org/10.1007/s11523-022-00906-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512879/
https://www.ncbi.nlm.nih.gov/pubmed/36114955
http://dx.doi.org/10.1007/s11523-022-00906-w

Ejemplares similares